Evidence map›Paper›PMID 36291881›Full record

ArticleCancers2022

Upregulation of Succinate Dehydrogenase (SDHA) Contributes to Enhanced Bioenergetics of Ovarian Cancer Cells and Higher Sensitivity to Anti-Metabolic Agent Shikonin.

Lin Wang, Magdalena Cybula, Maria Rostworowska, Luyao Wang, Patryk Mucha, Magdalena Bulicz, Magdalena Bieniasz

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. A bioinformatics approach to identify potential biomarkers of high-grade ovarian cancer.Journal of the Turkish German Gynecological Association · 2026
    Article
  4. Article
  5. Article
  6. Subcellular Stress Markers in Epithelial Ovarian Cancer.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Interplay between altered metabolism and DNA damage and repair in ovarian cancer.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lin WangAging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Magdalena CybulaAging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Maria RostworowskaAging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Luyao WangAging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Patryk MuchaAging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Magdalena BuliczAging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.ORCID 0000-0002-2460-0321
Magdalena BieniaszAging and Metabolism Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.ORCID 0000-0001-7230-9881
Oklahoma Medical Research Foundation · US

Funding

Viral sensor IFIH1 promotes SLE through an altered interferon programP20GM139763 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Kenneth M Humphries · 2021 to 2026
$20.3M
Targeting sfRon-S6K1 signaling and mitotic kinesin Eg5 in ovarian cancer: a novel synergistic treatment strategyR21CA264573 · NCI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI BIENIASZ, MAGDALENA · 2021 to 2022
$445k
NCI NIH HHS R21 CA264573NIGMS NIH HHS P20 GM139763NIH HHS 1 P20 GM139763-01NIH HHS R21 CA264573-01A
6 · The paper itself

Abstract

We discovered that the overexpression of mitochondrial enzyme succinate dehydrogenase (SDHA) is particularly prevalent in ovarian carcinoma and promotes highly metabolically active phenotype. Succinate dehydrogenase deficiency has been previously studied in some rare disorders. However, the role of SDHA upregulation and its impact on ovarian cancer metabolism has never been investigated, emphasizing the need for further research. We investigated the functional consequences of SDHA overexpression in ovarian cancer. Using proteomics approaches and biological assays, we interrogated protein content of metabolic pathways, cell proliferation, anchorage-independent growth, mitochondrial respiration, glycolytic function, and ATP production rates in those cells. Lastly, we performed a drug screening to identify agents specifically targeting the SDHA overexpressing tumor cells. We showed that SDHA overexpressing cells are characterized by enhanced energy metabolism, relying on both glycolysis and oxidative phosphorylation to meet their energy needs. In addition, SDHA-high phenotype was associated with cell vulnerability to glucose and glutamine deprivation, which led to a substantial reduction of ATP yield. We also identified an anti-metabolic compound shikonin with a potent efficacy against SDHA overexpressing ovarian cancer cells. Our data underline the unappreciated role of SDHA in reprogramming of ovarian cancer metabolism, which represents a new opportunity for therapeutic intervention.

Indexed as

metabolismovarian cancerpatient-derived xenograftSDHAshikoninsuccinate dehydrogenase

Identifiers

PMID36291881
PMCPMC9599980
OpenAlexW4306736762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.